Board of Directors

Wenche Rolfsen
Wenche Rolfsen
Chairman of the board since September 2017; chairman of the Remuneration Committee

Wenche Rolfsen has 30 years of experience in senior positions in preclinical research and development at Pharmacia. She was responsible for the early clinical organization at Quintiles Europe and CEO of Quintiles Scandinavia for a total of 11 years. She also has extensive experience from board positions in listed companies and is a member of the board of Swedish Match AB and Recipharm AB, among others.

Born: 1952
Education: Pharmacist, Doctor of pharmacy (pharmacognosy), Adjunct Professor at Uppsala University
Background: Head of pharmacology at Pharmacia & Upjohn; VP clinical trials Quintiles Europe, CEO of Scandinavian Quintile’s organization
Other current assignments: Chairman of InDex Pharmaceuticals Holding AB, InDex Pharmaceuticals AB and Sarsia Seed Fund, Norway; board member of Swedish Match AB, Recipharm AB and InDex Diagnostics AB, and CEO and board member of Rolfsen Consulting AB. Partner in Serendipity Partners
Prior assignments (past five years): CEO of InDex Pharmaceuticals AB, chairman of Aprea Therapeutics AB, Denator AB, Aprea Personal AB, Smartfish AB and board member of Moberg Pharma AB, TFS Trial Form Support International AB and Apotek Produktion & Laboratorier AB
Holdings: 19,200 B-shares and 1,818 call options entitling to the acquisition of 27,270 B-shares

Independent in relation to BioArctic, its senior management and major shareholders

Ivar Verner
Ivar Verner
Deputy chairman since 2017, board member since 2010, chairman of the Audit Committee

Ivar Verner is chairman of the board of Rejlers AB (publ) and former certified public accountant, partner and chairman of the board of Grant Thornton Sweden AB.

Born: 1947
Education: Master of Business Administration, Stockholm School of Economics
Background: Former certified public accountant, partner and chairman of Grant Thornton Sweden AB
Other assignments: Chairman of Erlandssons Brygga AB, Centrum Fastigheter i Norrtälje AB, Norrländska Gruppbostäder Holding AB, Tegnér & Son AB, Firren AB and Valsättra Exploaterings AB. Board member of Förvaltningsaktiebolaget Kanalen, Verner & Partners AB, Casa Firmus Holding AB and Valsättra Tomter AB
Prior assignments (past five years): Chairman of Rejlers AB (publ), Welcome Hotel i Sverige AB, Constrera AB and SpineMedical AB. Board member of Forex Bank AB and Svenska Vårdfastigheter AB
Holdings: 72,500 B-shares through Förvaltningsaktiebolaget Kanalen AB and 1,818 call options entitling to the acquisition of 27,270 B-shares

Independent in relation to BioArctic, its senior management and major shareholders

Hans Ekelund
Hans Ekelund
Board member since 2014, member of the Audit Committee and the Remuneration Committee

Hans Ekelund has an MBA from Stockholm School of Economics. He has had a number of assignments as board member and has previously been CFO of Ratos.

Born: 1948
Education: Master of Business Administration, Stockholm School of Economics
Background: Previously CFO of Ratos and a number of assignments as board member
Other assignments: Chairman of Connect Öst (non-profit organization) and board member of Ekarna Invest AB
Prior assignments (past five years): Chairman of Minimarket Stockholm AB and chairman and deputy board member of Wave Impact Heat Management AB. Board member of SpineMedical Sverige AB and SpineMedical AB
Holdings: 42,500 B-shares through Ekarna Invest AB and 1,818 call options entitling to the acquisition of 27,270 B-shares

Independent in relation to BioArctic, its senior management and major shareholders

Pär Gellerfors
Pär Gellerfors
Board member since 2003

Pär Gellerfors is together with Lars Lannfelt the founder of BioArctic. Gellerfors is Associate Professor of Biochemistry at Stockholm University. He is also co-founder of HemeBiotech/Zymenex A/S and has held several board memberships. Gellerfors is employed by the Company and responsible for business strategy. He is also co-opted member of the Senior management team.

Born: 1947
Education: Bachelor degree in chemistry at Stockholm University 1967; PhD in chemistry at Stockholm University 1977; Associate Professor of Biochemistry at Stockholm University 1983
Background: One of the founders of BioArctic in 2003 and CEO from 2003 to 2013. Now Senior Vice President Business Strategy and co-opted member of the management team. More than 30 years’ experience of drug and business development from Pharmacia and biotech companies. Co-founder of HemeBiotech/Zymenex A/S
Other assignments: CEO and board member of Swenora Biotech AB, board member of Ackelsta AB, LPB Sweden AB and deputy board member of Otwomed AB
Prior assignments (past five years): CEO and board member of SpineMedical Sverige AB and SpineMedical AB and board member of LPB Sweden Holding AB
Holdings: 5,759,998 A-shares and 15,232,989 B-shares through Ackelsta AB

Dependent in relation to BioArctic, its senior management and in relation to major shareholders

Lars Lannfelt
Lars Lannfelt
Board member since 2003

Lars Lannfelt is together with Pär Gellerfors the founder of BioArctic. Lannfelt is Senior Professor at Uppsala University and also a member of The Royal Swedish Academy of Sciences.

Born: 1949
Education: Medical degree 1978; specialist in psychiatry 1987; doctoral thesis at Karolinska Institutet 1990; Associate Professor of Neurogenetics at Karolinska Institutet 1993; specialist in geriatrics 2000
Background: Professor of Geriatrics at Uppsala University 2001; Senior Professor at Uppsala University 2016 and member of The Royal Swedish Academy of Sciences since 2004. One of the founders of BioArctic in 2003, chairman of the board 2003-2017 (September) and a number of assignments and roles in the company
Other assignments: Board member of Demban AB and LPB Sweden AB
Prior assignments (past five years): Board member of Demban Förvaltning AB, SpineMedical Sverige AB, SpineMedical AB and LPB Sweden Holding AB
Holdings: 8,639,998 A-shares and 22,848,159 B-shares through Demban AB

Dependent in relation to BioArctic, its senior management and in relation to major shareholders

Mikael Smedeby
Mikael Smedeby
Board member since May 2018

Mikael Smedeby is a lawyer and Managing Partner of Advokatfirman Lindahl, Uppsala, where he has been active since 1997 and in leading positions since 2010. For several years Mikael Smedeby has been ranked as “leading” in life sciences in Sweden by Practical Law Company and he is co-chairman of the life sciences practice group within TerraLex, a global network of independent law firms

Born: 1968
Education: Master of Laws, Uppsala University
Background: Active as a lawyer since 1994, with Advokatfirman Lindahl since 1997, member of the Swedish Bar Association since 1999. Since 2010, leading positions at Advokatfirman Lindahl, as managing partner and chairman, among others. Special experience in corporate law, mergers and acquisitions, financing and licensing, with many clients in the life sciences sector. Member of BioArctic’s board of directors 2014 – June 2017, extensive experience of board work in companies outside life sciences
Other assignments: Chairman of the Board in Hanza Holding AB, Coeli Holding AB, Salléngruppen AB. Board member of Uppsala Innovation Centre AB and Disruptive Materials AB
Holdings: 10,000 B-shares and 1,818 call options entitling to the acquisition of 27,270 B-shares

Not independent in relation to BioArctic and the company’s senior executives as a result of Advokatfirman Lindahl’s assignment as advisors to BioArctic

Eugen Steiner
Eugen Steiner
Board member since 2017, member of the Audit Committee and the Remuneration Committee

Eugen Steinar has 30 years experience of leading life science companies. Prior to that he was active as a doctor at Karolinska Hospital (Huddinge) and a researcher at Karolinska Institutet. As a venture partner to HealthCap since 1997, he has been CEO of certain companies in which HealthCap has invested. He has extensive experience from board positions in Sweden, Norway, England and the United States.

Born: 1954
Education: Medical doctor, PhD in clinical pharmacology at Karolinska Institutet
Background: 30 years’ experience of leading life science companies. Prior to that active as a doctor at Karolinska Hospital (Huddinge) and researcher at Karolinska Institutet. Venture partner to HealthCap since 1997 and CEO of several companies in which HealthCap has invested. Extensive experience from board positions in Sweden, Norway, the UK and the US
Other assignments: CEO and chairman of NVC Holding AB and CEO of Glionova AB. Board member of Apotek Produktion & Laboratorier AB, Inbox Capital AB, Stiftelsen Forska!Sverige, Stockholm School of Entrepreneurship and Setraco AB Deputy board member of Doctrin AB
Prior assignments (past five years): CEO and board member substitute of Optivy Sweden AB, CEO of Nordic Vision Clinics AS and chairman of Biostratum Inc., LTB4 Sweden AB, CC10 Sweden AB, Globen Ögonklinik AB and PanSyn Sweden AB Board member of Alba Therapeutics Inc., Hanza Holding AB, MD International AB, Nephrogenex Inc. and Praktikertjänst Aktiebolag
Holdings: 40,000 B-shares through Setraco AB and 1,818 call options entitling to the acquisition of 27,270 B-shares

Independent in relation to BioArctic, its senior management and major shareholders

Holdings in BioArctic AB as of December 31, 2017.